公开(公告)号：WO2021212015A2

公开(公告)日：2021-10-21

申请号：PCT/US2021/027751

申请日：2021-04-16

Applicant: LINEAGE CELL THERAPEUTICS, INC. ,  SEN, Debasish ,  NISHIMOTO, Kevin P. ,  CASE, Casey C. ,  LEBKOWSKI, Jane S.

Inventor： SEN, Debasish ,  NISHIMOTO, Kevin P. ,  CASE, Casey C. ,  LEBKOWSKI, Jane S.

IPC: A61K39/00 ,  C12N5/0784

Abstract: The present disclosure provides immunogenic telomerase reverse transcriptase-derived peptide compositions and methods of their use. By administering to a human subject an effective amount of an immunotherapeutic composition that stimulates an immune response to one or more peptides in the composition, a cell-mediated immune response may be elicited in the subject.

公开(公告)号：WO2007144140A1

公开(公告)日：2007-12-21

申请号：PCT/EP2007/005172

申请日：2007-06-12

Applicant: CELL THERAPEUTICS EUROPE S.r.l. ,  CELL THERAPEUTICS, INC. ,  MCKENNON, Marc ,  DA RE, Giovanni ,  FELICIOTTI, Luca ,  ARTICO, Marco ,  PARDI, Gianluca ,  GRUGNI, Mario

Inventor： MCKENNON, Marc ,  DA RE, Giovanni ,  FELICIOTTI, Luca ,  ARTICO, Marco ,  PARDI, Gianluca ,  GRUGNI, Mario

IPC: C07K14/00 ,  C08G69/10 ,  C07K1/00 ,  A61K47/48

CPC classification number: C07K14/001 ,  C08G69/10

Abstract: The invention relates to an improved process for the preparation of poly-α-glutamic acids which comprises the polymerisation of tertiary γ-esters of α-glutamic acid N-carboxy anhydride with appropriate solvents and initiators, followed by acid hydrolysis of the resulting poly-α-glutamic acid-γ-ester. The process is particularly advantageous in that it allows to carefully control the molecular weight of the resulting poly-α-glutamic acid. The invention also relates to poly-α-glutamic acids capped at the amino terminus with carboxylic acids or amino acids and to a process for the preparation thereof.

Abstract translation: 本发明涉及一种用于制备聚谷氨酸的改进方法，其包括用合适的溶剂和引发剂将α-谷氨酸N-羧酸酐的叔α-酯聚合，然后酸化所得聚 - α-谷氨酸-β-酯。 该方法是特别有利的，因为其允许仔细控制所得聚-α-谷氨酸的分子量。 本发明还涉及在氨基末端被羧酸或氨基酸封端的聚-A-谷氨酸及其制备方法。

公开(公告)号：WO2006081249A8

公开(公告)日：2007-09-13

申请号：PCT/US2006002501

申请日：2006-01-25

Applicant: CELL THERAPEUTICS INC ,  BESMAN MARC ,  CHIPMAN STEWART ,  LEUNG DAVID ,  SINGER JACK

Inventor： BESMAN MARC ,  CHIPMAN STEWART ,  LEUNG DAVID ,  SINGER JACK

IPC: C07K14/435

CPC classification number: C07K14/47 ,  A61K38/00

Abstract: Disclosed are biologically active protein conjugates that comprise a biologically active polypeptide coupled via a peptide bond to a polypeptide comprising from 2 to about 500 units of a repeating peptide motif, wherein the biologically active protein conjugate exhibits a modified plasma half-life compared to the intrinsic half-life of the unconjugated biologically active polypeptide or protein. Also disclosed are methods of making and using the conjugated proteins, as well as methods for determining whether a given conjugate exhibits a modified half life relative to the intrinsic half life of the unconjugated polypeptide.

Abstract translation: 公开了包含生物活性蛋白质缀合物的生物活性蛋白质缀合物，所述生物活性多肽通过肽键与包含2至约500个重复肽基序单元的多肽偶联，其中所述生物活性蛋白质缀合物显示与内源性相比改变的血浆半衰期 未缀合的生物活性多肽或蛋白质的半衰期。 还公开了制备和使用缀合蛋白的方法，以及用于确定给定缀合物是否表现出相对于未缀合多肽的内在半衰期的修饰半衰期的方法。

公开(公告)号：WO2006081249A2

公开(公告)日：2006-08-03

申请号：PCT/US2006002501

申请日：2006-01-25

Applicant: CELL THERAPEUTICS INC ,  BESMAN MARC ,  CHIPMAN STEWART ,  LEUNG DAVID

Inventor： BESMAN MARC ,  CHIPMAN STEWART ,  LEUNG DAVID

CPC classification number: C07K14/47 ,  A61K38/00

Abstract: Disclosed are biologically active protein conjugates that comprise a biologically active polypeptide coupled via a peptide bond to a polypeptide comprising from 2 to about 500 units of a repeating peptide motif, wherein the biologically active protein conjugate exhibits a modified plasma half-life compared to the intrinsic half-life of the unconjugated biologically active polypeptide or protein. Also disclosed are methods of making and using the conjugated proteins, as well as methods for determining whether a given conjugate exhibits a modified half life relative to the intrinsic half life of the unconjugated polypeptide.

Abstract translation: 公开了生物活性蛋白质缀合物，其包含通过肽键与多肽偶联的生物活性多肽，所述多肽包含2至约500个单位的重复肽基序，其中所述生物活性蛋白质缀合物与内在的 未缀合的生物活性多肽或蛋白质的半衰期。 还公开了制备和使用共轭蛋白的方法，以及用于确定给定缀合物相对于未缀合多肽的固有半衰期显示修饰的半衰期的方法。

公开(公告)号：WO2004011021A1

公开(公告)日：2004-02-05

申请号：PCT/CA2003/001181

申请日：2003-07-31

Applicant: STEM CELL THERAPEUTICS INC. ,  ANDERSEN, Linda, B. ,  SHINGO, Tetsuro ,  WEISS, Samuel

Inventor： ANDERSEN, Linda, B. ,  SHINGO, Tetsuro ,  WEISS, Samuel

IPC: A61K38/18

CPC classification number: A61K38/1808 ,  A61K38/1816 ,  A61K2300/00

Abstract: Methods are described for the enhancement and/or induction of migration of neural stem cells or neuronal progenitor cells. Multipotent neural stem cells are exposed to erythropoietin which enhances the migration of multipotent neural stem cells and neuronal progenitor cells. The erythropoietin may be exogenously applied to the multipotent neural stem cells, or alternatively, the cells can be subjected to hypoxic insult which induces the cells to express erythropoietin. In a preferred embodiment, additional growth factors, such as EGF and prolactin, are utilized.

Abstract translation: 描述了用于增强和/或诱导神经干细胞或神经元祖细胞迁移的方法。 多能神经干细胞暴露于红细胞生成素，其增强多能神经干细胞和神经元祖细胞的迁移。 促红细胞生成素可以外源施用于多能神经干细胞，或者，细胞可以进行缺氧诱导，诱导细胞表达促红细胞生成素。 在优选的实施方案中，使用另外的生长因子，例如EGF和催乳素。

公开(公告)号：WO03024472A3

公开(公告)日：2003-09-18

申请号：PCT/CA0201345

申请日：2002-08-30

Applicant: STEM CELL THERAPEUTICS INC ,  WEISS SAMUEL ,  SHINGO TETSURO

Inventor： WEISS SAMUEL ,  SHINGO TETSURO

IPC: A61L27/00 ,  A61K31/565 ,  A61K35/12 ,  A61K35/30 ,  A61K38/00 ,  A61K38/22 ,  A61K38/27 ,  A61K38/30 ,  A61P21/00 ,  A61P25/00 ,  A61P25/14 ,  A61P25/16 ,  A61P25/28 ,  C12N5/0797 ,  C12N5/06 ,  C12N5/08

CPC classification number: C12N5/0623 ,  A61K35/12 ,  A61K38/2257 ,  A61K38/27 ,  A61K38/30 ,  A61K2300/00

Abstract: The present invention provides a method of increasing neural stem cell numbers or neurogenesis by using prolactin. The method can be practiced in vivo to obtain more neural stem cells in situ, which can in turn produce more neurons or glial cells to compensate for lost or dysfunctional neural cells. The method can also be practiced in vitro to produce a large number of neural stem cells in culture. The cultured stem cells can be used, for example, for transplantation treatment of patients or animals suffering from neurodegenerative diseases or conditions. In addition, since neural stem cells are a source for olfactory neurons, the present invention also provides methods of increasing olfactory neurons and enhancing olfactory functions.

Abstract translation: 本发明提供了通过使用催乳素来增加神经干细胞数量或神经发生的方法。 该方法可以在体内实施以获得更多的原位神经干细胞，其又可产生更多的神经元或神经胶质细胞以补偿丢失或功能失调的神经细胞。 该方法也可以在体外实施以在培养物中产生大量的神经干细胞。 培养的干细胞可用于例如患有神经变性疾病或病症的患者或动物的移植治疗。 此外，由于神经干细胞是嗅觉神经元的来源，本发明还提供了增加嗅觉神经元和增强嗅觉功能的方法。

公开(公告)号：WO2003024471A2

公开(公告)日：2003-03-27

申请号：PCT/CA2002/001344

申请日：2002-08-30

Applicant: STEM CELL THERAPEUTICS INC. ,  WEISS, Samuel ,  SHINGO, Tetsuro

Inventor： WEISS, Samuel ,  SHINGO, Tetsuro

IPC: A61K38/00

CPC classification number: C12N5/0623 ,  A61K35/12 ,  A61K38/1816 ,  A61K38/2257 ,  A61K38/27 ,  A61K38/30 ,  A61K2300/00

Abstract: The present invention provides a method of increasing neural stem cell numbers by using growth hormone and/or IGF-l. The method can be practiced in vivo to obtain more neural stem cells in situ , which can in turn produce more neurons or glial cells to compensate for lost or dysfunctional neural cells. The method can also be practiced in vitro to produce a large number of neural stem cells in culture. The cultured stem cells can be used, for example, for transplantation treatment of patients or animals suffering from neurodegenerative diseases or conditions.

Abstract translation: 本发明提供了通过使用生长激素和/或IGF-1增加神经干细胞数量的方法。 该方法可以在体内实施以获得更多的原位神经干细胞，其又可产生更多的神经元或神经胶质细胞以补偿丢失或功能失调的神经细胞。 该方法也可以在体外实施以在培养物中产生大量的神经干细胞。 培养的干细胞可用于例如患有神经变性疾病或病症的患者或动物的移植治疗。

公开(公告)号：WO2003018782A3

公开(公告)日：2003-03-06

申请号：PCT/CA2002/001346

申请日：2002-08-30

Applicant: STEM CELL THERAPEUTICS INC. ,  THOMPSON, Bradley, G. ,  WEISS, Samuel ,  SHINGO, Tetsuro

Inventor： THOMPSON, Bradley, G. ,  WEISS, Samuel ,  SHINGO, Tetsuro

IPC: C12N5/06

Abstract: This invention relates to a method of selectively producing neural cells, including neurons or glial cells, in vitro or in vivo . Also provided are methods of treating or ameliorating neurodegenerative disease or medical conditions by producing neural cells. Thus, a combination of factors is used to achieve two steps: increasing the number of neural stem cells and instructing the neural stem cells to selectively become neurons or glial cells.

公开(公告)号：WO2002094824A1

公开(公告)日：2002-11-28

申请号：PCT/US2002/012791

申请日：2002-04-24

Applicant: CELL THERAPEUTICS, INC.

Inventor： MCKENNON, Marc, J. ,  KLEIN, J., Peter ,  COON, Michael

IPC: C07D471/04

CPC classification number: C07D471/04

Abstract: Novel pyridopyrimidine-based compounds are found to be useful for the treatment or prevention of symptoms or manifestations associated with diseases or disorders affected by cytokine intracellular signaling, having the following formula: formula (I) wherein R 1 is selected from a member of the group consisting of hydrogen, hydroxyl, methoxyl, N-OH, acylamino group, cyano group, sulfo, sulfonyl, sulfinyl, sulfhydryl (mercapto), sulfeno, sulfanilyl, sulfamyl, sulfamino, and phosphino, phosphinyl, phospho phosphono and -NR a R b , wherein each of Ra and Rb may be the same or different and each is selected from the group consisting of hydrogen and optionally substituted: C (1-20) alkyl, C (1-20) cycloalkyl, C (1-20) alkenyl, C (1-20) cycloalkenyl, C (1-20) alkynyl, aryl, heteroaryl, and heterocyclic group. R 2 and R 3 are independently selected from a member of the group consisting of halo, thio, oxo, C (1-20) alkyl, C (1-20) hydroxyalkyl, C (1-20) thioalkyl, C (1-20) alkylthio, C (1-20) alkylamino, C (1-20) alkylaminoalkyl, C (1-20) aminoalkyl, C (1-20) aminoalkoxyalkenyl, C (1-20) aminoalkoxyalkynyl, C (1-20) diaminoalkyl, C (1-20) triaminoalkyl, C (1-20) tetraaminoalkyl, C (1-20) aminotrialkoxyamino, C (1-20) alkylamido, C (1-20) alkylamidoalkyl, C (1-20) amidoalkyl, C (1-20) acetamidoalkyl, C (1-20) alkenyl, C (1-20) alkynyl, C (1-20) alkoxyl, C (1-20) alkoxyalkyl, C (1-20) dialkoxyalkyl, and Nr a R b . R 4 may be hydrogen or an optionally substituted member of the group consisting of C (1-20) alkyl, C (1-20) cycloalkyl, C (1-20) alkenyl, C (1-20) cycloalkenyl, C (1-20) alkynyl, aryl, heteroaryl, and heterocyclic group.

Abstract translation: 发现新的吡啶并嘧啶类化合物可用于治疗或预防与受细胞因子细胞内信号传导影响的疾病或病症有关的症状或表现，其具有下式：其中R1选自下组成员： 氢，羟基，甲氧基，N-OH，酰氨基，氰基，磺基，磺酰基，亚磺酰基，巯基，磺酰基，磺酰基，氨基磺酰基，磺氨基和膦基，氧膦基，磷酰基和-NRaRb， R 1和R 2可以相同或不同，各自选自氢和任选取代的C（1-20）烷基，C（1-20）环烷基，C（1-20）烯基，C（1） -20）环烯基，C（1-20）炔基，芳基，杂芳基和杂环基。 R 2和R 3独立地选自卤素，硫代，氧代，C（1-20）烷基，C（1-20）羟基烷基，C（1-20）硫代烷基，C（1-20） （1-20）烷基氨基烷基，C（1-20）氨基烷基，C（1-20）氨基烷氧羰基，C（1-20）氨基烷氧基炔基，C（1-20）二氨基烷基， （1-20）三氨基烷基，C（1-20）四氨基烷基，C（1-20）氨基三烷氧基氨基，C（1-20）烷基酰胺基，C（1-20）烷基酰氨基烷基，C（1-20） 1-20）乙酰氨基烷基，C（1-20）烯基，C（1-20）炔基，C（1-20）烷氧基，C（1-20）烷氧基烷基，C（1-20）二烷氧基烷基和NraRb。 R 4可以是氢或任选取代的C（1-20）烷基，C（1-20）环烷基，C（1-20）烯基，C（1-20）环烯基，C（1- 20）炔基，芳基，杂芳基和杂环基。

公开(公告)号：WO2002068421A2

公开(公告)日：2002-09-06

申请号：PCT/US2001/043048

申请日：2001-11-09

Applicant: CELL THERAPEUTICS, INC. ,  GONG, Baoqing ,  KLEIN, J., Peter ,  COON, Michael

Inventor： GONG, Baoqing ,  KLEIN, J., Peter ,  COON, Michael

IPC: C07D487/00

CPC classification number: C07D487/14 ,  A61K31/522 ,  A61K31/675 ,  C07D513/14

Abstract: Novel tricyclic compounds are found to be useful for the treatment or prevention of symptoms or manifestations associated with diseases or disorders affected by cytokine intracellular signaling.

Abstract translation: 具有式（II）或（I）的新型三环化合物，其中：R 1任选被取代并选自氢，甲基，C 1-20烷基，C 1-20烯基，C 1-20炔基，C 1-20羟烷基， C 1-20烷酰基，C 1-20烷氧基烷基和C 1-20烷氧基烷基R 2和R 3连接形成任选取代的杂环，每个R 2和R 3独立地选自氢，卤素，硫代，氧代，C 1-20烷基， C 1-20烷氧基烷基，C 1-20二氨基烷基，C 1-20二氨基烷基，C 1-20二氨基烷基，C 2-20氨基三烷氧基氨基，C 1 -C 20烷基氨基烷基， 20个烷基酰氨基，C 1-20烷基酰氨基烷基，C 1-20氨基烷基，C 1-20乙酰胺基烷基，C 1-20烯基，C 1-20炔基，C 1-20烷氧基，C 1-20烷氧基烷基和C 1-20二烷氧基烷基被用于治疗或预防相关表现的症状 与疾病或病症affec 由胞嘧啶和细胞内信号传导。